Respiri (ASX:RSH) confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.
It said that it has already over two years' worth of inventory for its wheezo device in the US.
While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.
It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.